Solvay Pharmaceuticals has renewed its clinical development alliance with Quintiles Transnational Corp. for another five years. First signed in 2001, the renewal reflects the success in accelerating development of Solvay’s product portfolio and improving efficiency. Through the alliance, Solvay has completed three Phase III programs, moved two compounds from Phase II to Phase III earlier than expected, and produced conclusive Phase II data that resulted in the termination of two other...